Kissei's overactive bladder drug fails Phase III trial
This article was originally published in Scrip
The future of a novel overactive bladder (OAB) drug being developed by the mid-sized Japanese firm Kissei has been thrown into doubt after the molecule missed its primary endpoint in a Phase III clinical study.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.